veonetinib (AL8326) / Advenchen - LARVOL DELTA

A Study of AL58805 in Advanced, Metastatic GYN, STS or Breast Cancers (clinicaltrials.gov) - P1/2 | N=138 | Not yet recruiting | Sponsor: Advenchen Pharmaceuticals, LLC.

dMMR • MSI-H • New P1/2 trial • Breast Cancer • Endometrial Cancer • Oncology • Sarcoma • Soft Tissue Sarcoma • Solid Tumor • MSI

Phase 2 Study for the Patient, Who Has Diagnosed With Small Cell Lung Cancer (SCLC) or Non Small Cell Lung Cancer (NSCLC) or Renal Cell Carcinoma (RCC) and Finished the First Line Stand Treatment , Need More Treatment (clinicaltrials.gov) - P2 | N=80 | Recruiting | Sponsor: Advenchen Pharmaceuticals, LLC. | N=36 ➔ 80 | Trial completion date: Dec 2026 ➔ Dec 2028 | Trial primary completion date: Dec 2025 ➔ Dec 2027 | Active, not recruiting ➔ Recruiting

Enrollment change • Enrollment open • Trial completion date • Trial primary completion date • Genito-urinary Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Renal Cell Carcinoma • Small Cell Lung Cancer • Solid Tumor

Evaluation of the safety and efficacy of the drug Veonetinib (AL8326) in the post-first treatment of small cell lung cancer, non small cell lung cancer and renal cell carcinoma. (clinicaltrials.gov) - P2 | N=50 | Active, not recruiting | Sponsor: Advenchen Pharmaceuticals, LLC. | N=30 ➔ 50 | Recruiting ➔ Active, not recruiting

Enrollment change • Enrollment closed • Clear Cell Renal Cell Carcinoma • Genito-urinary Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Renal Cell Carcinoma • Small Cell Lung Cancer • Solid Tumor

A Phase I/IIa Study of AL8326 Combined With Toripalimab in the Treatment of Advanced Solid Tumors. (clinicaltrials.gov) - P1/2 | N=228 | Recruiting | Sponsor: Advenchen Laboratories, LLC

New P1/2 trial • Solid Tumor

Phase 2 Safety and Efficacy Evaluation of AL8326 in ≥2nd Line SCLC (clinicaltrials.gov) - P2 | N=36 | Active, not recruiting | Sponsor: Advenchen Pharmaceuticals, LLC. | Recruiting ➔ Active, not recruiting | Trial completion date: Dec 2025 ➔ Dec 2026 | Trial primary completion date: Dec 2024 ➔ Dec 2025

Enrollment closed • Trial completion date • Trial primary completion date • Lung Cancer • Oncology • Small Cell Lung Cancer • Solid Tumor

A Phase IIII Study of AL8326 in Small Cell Lung Cancer (clinicaltrials.gov) - P3 | N=243 | Recruiting | Sponsor: Advenchen Laboratories Nanjing Ltd.

Metastases • New P3 trial • Lung Cancer • Oncology • Small Cell Lung Cancer • Solid Tumor

AL8326 in SCLC Treatment (clinicaltrials.gov) - P2 | N=36 | Recruiting | Sponsor: Advenchen Pharmaceuticals, LLC. | Trial completion date: Dec 2024 ➔ Dec 2025 | Trial primary completion date: Dec 2023 ➔ Dec 2024

Trial completion date • Trial primary completion date • Lung Cancer • Oncology • Small Cell Lung Cancer • Solid Tumor

Phase Ib/IIa study assessing the safety and efficacy of AL8326 monotherapy in patients with ≥3rd line small cell lung cancer (SCLC) treatment. (ASCO 2023) - P1/2, P2 | "AL8326 has demonstrated acceptable tolerability and positive efficacy on small cell lung cancer treatment. A US Phase 2 (NCT05363280) study is ongoing and a phase 3 study is in preparation. Clinical trial information: NCT04890795."

Clinical • Monotherapy • P1/2 data • Anorexia • Cardiovascular • Dyslipidemia • Hematological Disorders • Hypertension • Hypertriglyceridemia • Lung Cancer • Metabolic Disorders • Neuroendocrine Tumor • Oncology • Renal Disease • Small Cell Lung Cancer • Solid Tumor • Thrombocytopenia

AL8326 in SCLC Treatment (clinicaltrials.gov) - P2 | N=36 | Recruiting | Sponsor: Advenchen Pharmaceuticals, LLC. | Not yet recruiting ➔ Recruiting

Enrollment open • Lung Cancer • Neuroendocrine Tumor • Oncology • Small Cell Lung Cancer • Solid Tumor

AL8326 in SCLC Treatment (clinicaltrials.gov) - P2 | N=36 | Not yet recruiting | Sponsor: Advenchen Pharmaceuticals, LLC. | Initiation date: Jul 2022 ➔ Nov 2022

Trial initiation date • Lung Cancer • Neuroendocrine Tumor • Oncology • Small Cell Lung Cancer • Solid Tumor

A Study of Diet Influence of AL8326 in Chinese Healthy Adult Subjects (clinicaltrials.gov) - P1 | N=16 | Recruiting | Sponsor: Advenchen Laboratories Nanjing Ltd.

New P1 trial

AL8326 in SCLC Treatment (clinicaltrials.gov) - P2 | N=36 | Not yet recruiting | Sponsor: Advenchen Pharmaceuticals, LLC.

New P2 trial • Lung Cancer • Neuroendocrine Tumor • Oncology • Small Cell Lung Cancer • Solid Tumor

A Phase I Study of AL8326 in Advanced Solid Tumor (clinicaltrials.gov) - P1; N=40; Recruiting; Sponsor: Advenchen Laboratories Nanjing Ltd.

New P1 trial • Breast Cancer • Colorectal Cancer • Gastrointestinal Cancer • Head and Neck Cancer • Oncology • Ovarian Cancer • Renal Cell Carcinoma • Solid Tumor

A Phase Ib / IIA Study of AL8326 in Small Cell Lung Cancer (clinicaltrials.gov) - P1/2; N=237; Recruiting; Sponsor: Advenchen Laboratories Nanjing Ltd.

Clinical • New P1/2 trial • Lung Cancer • Neuroendocrine Tumor • Oncology • Small Cell Lung Cancer • Solid Tumor